Nystatin Dosing and Prescribing Guidance

Oral Candidiasis – Suspension Regimen

In patients with oral candidiasis, prescribe nystatin oral suspension (100,000 U/mL) at 4 mL four times daily for 7 days (total 112 mL) or 6 mL four times daily for 14 days (total 336 mL) to ensure complete eradication. Strong recommendation, moderate‑quality evidence from the Infectious Diseases Society of America (IDSA) 1
Choose bottle size to match the calculated total volume (60 mL bottle for a 7‑day course; 480 mL bottle for a 14‑day course) to avoid under‑supply. Strong recommendation, moderate‑quality evidence IDSA 1

For patients preferring a solid dosage form, use nystatin pastilles (200,000 U each) at 1–2 pastilles four times daily for 7–14 days; a 14‑day course requires 112 pastilles. Strong recommendation, moderate‑quality evidence IDSA 1

In cases of C. glabrata vulvovaginitis that do not respond to oral azoles, prescribe intravaginal nystatin suppositories (100,000 U) once daily for 14 days (total 14 suppositories). Strong recommendation, low‑quality evidence IDSA 2
Reserve nystatin suppositories exclusively for azole‑refractory infections; they are not first‑line for uncomplicated vulvovaginal candidiasis. Strong recommendation, low‑quality evidence IDSA 2

Recommend topical azole agents or a single 150‑mg oral fluconazole dose as the first‑line treatment; nystatin is not indicated in this setting. Strong recommendation, low‑quality evidence IDSA 2

Nystatin has negligible systemic absorption and no pharmacologic interaction with insulin or other diabetes medications; therefore, no dose adjustment is required in diabetic patients. Strong recommendation, moderate‑quality evidence IDSA 1
Although diabetic patients have a higher susceptibility to oral candidiasis, the standard dosing (4–6 mL qid for 7–14 days) remains appropriate; monitor for treatment failure and consider switching to fluconazole if resistance emerges. Strong recommendation, moderate‑quality evidence IDSA 1

Underprescribing volume: prescribing a 60‑mL bottle for a 14‑day course at 6 mL qid would provide only 168 mL, insufficient for the required 336 mL total. Strong recommendation, moderate‑quality evidence IDSA 1
Inappropriate first‑line use for vulvovaginal candidiasis: using nystatin instead of topical azoles or fluconazole leads to suboptimal outcomes. Strong recommendation, low‑quality evidence IDSA 2
Ignoring recommended treatment duration: the IDSA advises 7–14 days of therapy; shorter courses risk incomplete eradication, especially in immunocompromised or diabetic individuals. Strong recommendation, moderate‑quality evidence IDSA 1